

UNIVERSITY OF COLORADO CANCER CENTER

Hematology-Oncology
1665 Aurora Court, Aurora CO 80045
Phone: 720-555-0500 | Fax: 720-555-0501
NPI: 1567893421

February 01, 2026

Blue Cross Blue Shield
Federal Employee Program
Prior Authorization Department
Medical Review Unit

RE: Letter of Medical Necessity

Patient Name:	Robert Hawkins
Date of Birth:	1971-11-03
Member ID:	FEP891245637
Group Number:	FEP-STANDARD-2024
Medication Requested:	Lisocabtagene maraleucel (Breyanzi)
Diagnosis:	Diffuse large B-cell lymphoma, unspecified site (C83.30)

To Whom It May Concern:

I am writing on behalf of my patient, Robert Hawkins, to document the medical necessity of Lisocabtagene maraleucel (Breyanzi) for the treatment of Diffuse large B-cell lymphoma, unspecified site. This letter provides clinical documentation supporting the need for this medication and demonstrates that my patient meets the coverage criteria for this therapy.

CLINICAL HISTORY AND DIAGNOSIS

54-year-old male with relapsed/refractory DLBCL and pre-existing mild congestive heart failure (HFmrEF, LVEF 45%). Originally diagnosed June 2024 with Stage IIIA DLBCL. Due to cardiac comorbidity (LVEF 45%, borderline for anthracycline use), first-line therapy was R-bendamustine (rituximab + bendamustine) x6 cycles instead of standard R-CHOP — doxorubicin was contraindicated per cardiology consultation. Achieved partial response but relapsed at 6 months. Second-line R-GemOx (rituximab, gemcitabine, oxaliplatin) x4 cycles with progressive disease. Not eligible for autologous transplant due to cardiac status. Now referred for CAR-T cell therapy.

CURRENT DISEASE ACTIVITY

Most recent assessment (2026-01-20):

- Ann Arbor Stage: IIIA
- Ecog Performance Status: 1
- Ecog Interpretation: Restricted in physically strenuous activity but ambulatory
- Ipi Score: 2
- Ipi Risk Category: Low-intermediate
- Disease Status: relapsed_refractory
- Lines Of Therapy Completed: 2

PRIOR TREATMENT HISTORY

The patient has tried and/or completed the following therapies:

- **R-Bendamustine** (2024-07-01 to 2024-12-15)

Outcome: Partial response (Deauville 3) at end of treatment. Used instead of R-CHOP due to cardiac contraindication to doxorubicin (anthracycline). Relapsed at 6 months with new supraclavicular and inguinal lymphadenopathy.

- **R-GemOx** (2025-07-01 to 2025-10-15)

Outcome: Progressive disease on restaging PET/CT with new hepatic and splenic lesions. Biopsy confirmed persistent DLBCL.

MEDICAL NECESSITY SUMMARY

Based on the clinical evidence presented, Lisocabtagene maraleucel (Breyanzi) is medically necessary for Robert Hawkins. The patient has a confirmed diagnosis of Diffuse large B-cell lymphoma, unspecified site (ICD-10: C83.30). Key criteria met: Biopsy-confirmed DLBCL (ICD-10 C83.30), CD19-positive; Patient is 54 years old (≥ 18); Rituximab included in both prior lines (R-bendamustine, R-GemOx); 2 prior lines of systemic therapy completed. I respectfully request approval of this prior authorization.

Please contact my office if you require any additional clinical information.

Sincerely,

Dr. Kevin Patel, MD, FACP

Hematology-Oncology

NPI: 1567893421

Date: 02/01/2026